IDH2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer

• Published in: Molecular oncology Vol. 12; no. 5; pp. 602 - 610
• Main Authors: Li, Jiang‐jiang, Li, Ruilei, Wang, Wenxiang, Zhang, Baihua, Song, Xin, Zhang, Chunfang, Gao, Yang, Liao, Qianjin, He, Ya, You, Shuo, Tan, Zheqiong, Luo, Xiangjian, Li, Yueshuo, Tang, Min, Weng, Xinxian, Yi, Wei, Peng, Shifang, Liu, Shaohui, Tan, Ying, Bode, Ann M., Cao, Ya
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2018; John Wiley and Sons Inc; Wiley
• Subjects: Cancer; Enzyme-linked immunosorbent assay; Health aspects; IDH2; Lung cancer, Non-small cell; Lung cancer, Small cell; Mortality; non‐small‐cell lung cancer; Oncology, Experimental; serum biomarker; serum biomarker; IDH2; non-small-cell lung cancer
• ISSN: 1574-7891; 1878-0261
• DOI: 10.1002/1878-0261.12182

Lung cancer is the most common leading cause of cancer‐related death worldwide. Late diagnosis contributes to a high mortality rate and poor survival of this cancer. In our previous study, we found that IDH2 polymorphism rs11540478 is a risk factor for lung cancer. Here, we examined IDH2 protein expression in culture medium in which two non‐small‐cell lung cancer (NSCLC) cell lines, H460 and A549, were growing. We found that the IDH2 protein was elevated in the culture supernatant fraction in a time‐ and cell number‐dependent manner. Next, we used ELISA methods to examine IDH2 protein level in serum from patients with NSCLC and healthy controls. We found that IDH2 protein levels in serum could distinguish NSCLC patients from healthy controls with an AUC (area under the curve) of 0.83 (95% confidence interval = 0.79–0.88). The IDH2 level was decreased in serum from NSCLC postsurgical patients compared with the paired presurgical serum. High serum IDH2 levels appear to correlate with poor survival in patients with NSCLC. These results suggest that IDH2 levels in the serum could be a new effective biomarker for the diagnosis and prognosis of NSCLC. Late diagnosis contributes to a high mortality rate and poor survival of lung cancer. Here, we found that serum IDH2 could distinguish NSCLC (mainly stage I) patients from healthy controls. High serum IDH2 levels correlated with poor survival in patients with NSCLC. These results suggest that serum IDH2 could be a new effective biomarker for the diagnosis and prognosis of NSCLC.